CG
TBPH icon

Cutler Group’s Theravance Biopharma TBPH Stock Holding History

Cutler Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,800
Closed -$1K – 6051
2021
Q3 		$1K Buy
+11,800
New +$132K ﹤0.01% 5440
2021
Q2 		– Sell
-2,500
Closed -$4K – 6327
2021
Q1 		$4K Buy
+2,500
New +$47.5K ﹤0.01% 4563
2020
Q2 		– Sell
-1,500
Closed -$3K – 4863
2020
Q1 		$3K Buy
+1,500
New +$37.5K ﹤0.01% 3358
2018
Q3 		– Sell
-5,000
Closed -$1K – 4673
2018
Q2 		$1K Hold
5,000
– – ﹤0.01% 3949
2018
Q1 		$4K Buy
+5,000
New +$137K ﹤0.01% 3438

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's TBPH Position: Q1 2022 in Review

Cutler Group sold out of Theravance Biopharma (TBPH) in Q1 2022, closing a stake of 8,623 shares — an estimated $84.5K sold.

Cutler Group first reported a position in TBPH in Q1 2019 and held it in 6 quarters. The position peaked at $288K in Q2 2019. 121 funds tracked by Wall St. Rank hold TBPH as of Q1 2022.

  • Cutler Group reported no remaining Theravance Biopharma position as of Q1 2022 after selling out during the quarter.
  • Cutler Group sold 8,623 Theravance Biopharma shares in Q1 2022, an estimated $84.5K.
  • Cutler Group first reported a position in Theravance Biopharma in Q1 2019 and held it in 6 quarters.
  • Cutler Group's Theravance Biopharma position peaked at $288K in Q2 2019.
  • 121 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2022.

Based on Cutler Group's 13F filing for Q1 2022, filed 14 Apr 2022.